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fast-track review." The company plans to
submit a product license application to the
FDA by the middle of 1999.
An UrgentNeed
Pneumococcal illnesses have traditionally
been treated with antibiotics. However,
drug-resistant strains ofpneumococcus have
become increasingly common in the United
States and other parts of the world, raising
the risk of untreatable complications or
death. Resistance to antibiotics such as peni-
cillin, erythromycin, sulfa drugs, and
cephalosporins has been reported.
According to principal investigator
Margaret Rennels, a professor of pediatrics
at the University of Maryland School of
Medicine in Baltimore, in some areas ofthe
United States, as many as 50% ofpneumo-
cocci are not sensitive to routine antibiotic
treatments. This emerging antimicrobial
resistance has "created an urgent need for a
vaccine [that is] effective in young chil-
dren," says pediatrician Henry Shinefield,
codirector with Steven Black of the Kaiser
Permanente Vaccine Study Center in
Oakland, California.
In a three-year Phase III clinical trial
involving 38,000 children, half of the
infants received the pneumococcal vaccine
by injection and halfreceived an ineffective
control vaccine at 23 Kaiser Permanente
sites in northern California. Each child was
dosed at 2, 4, and 6 months ofage, and a
booster dose was given at 12-15 months.
By the end ofthe study, 22 cases ofinvasive
pneumococcal disease (3 of meningitis and
19 ofbacteremia) had occurred in the con-
trol group. None had occurred in the vac-
cine group-an efficacy rate of 100%. The
only side effect was a mild fever lasting less
than aday.
"For those ofus who treat children with
meningitis and bacteremia, this is an enor-
mously exciting development," says
Rennels, who conducted earlier safety trials
ofthe vaccine. The results ofthe Phase III
trial were presented 25 September 1998 at
the "Interscience Conference on
Antimicrobial Agents and Chemotherapy,"
held in San Diego, California, and were
published in the April 1998 issue of
Pediatrics.
The new vaccine contains capsular
polysaccharides-the outer shell or coat of
a microbe that triggers an immune
response when injected-of 7 of the 80
known strains of S. pneumoniae. These
seven strains cause up to 85% of bac-
teremia and meningitis and 65% of otitis
media among young children. The vaccine
is based on the same technology used by
Wyeth Lederle to develop the Haemophilus
influenzae type b conjugate vaccine, which
Kiddie culprit. Streptococcus pneumoniae is the bacterium responsible for 7 million cases of otitis
media, the most common bacterial infection in children, in the United States each year.
was approved for use in infants in 1990.
The first experimental pneumococcal vac-
cine contained five serotypes ofS. pneumo-
niae (6B, 14, 18C, 19F, and 23F) conju-
gated to a carrier molecule called
CRM197, and was proven safe and
immunogenic in studies reported in
February 1996 in the Pediatric Infectious
DiseaseJournal. However, the addition of
serotypes 4 and 9V increased the percent-
age of prevented infections from 65% to
85%. The current vaccine, which contains
all seven serotypes conjugated to
CRM197, improves protection without
decreasing immunogenicity or increasing
adverse reactions.
For Kids Only
The first vaccine for pneumococcal disease
became available in 1944, but the advent of
penicillin and other antibiotics led to an
attitude that the need for vaccines would
become obsolete. However, antibiotic resis-
tance has rekindled interest invaccine devel-
opment. A pneumococcal vaccine for adults
has been available for 15 years, but is inef-
fective in children, especially those younger
than 2 years. The adult vaccine, generally
given to people over 65 who have chronic
debilitating illnesses, contains different
serotypes than the vaccine being developed
for children. "Adults get different pneumo-
coccal diseases than children get," explains
Shinefield.
It is believed that an effective pneumo-
coccal vaccine could help reduce health care
costs and curb the rise ofantibiotic-resistant
bacteria. On 4 May 1999, Shinefield and
colleagues announced at the Pediatric
Academy Society meeting in San Francisco,
California, that the vaccine also reduced
physician visits for otitis media by 9%. Half
ofall cases ofacute otitis media, accounting
for 12 million visits to pediatricians in the
United States, are caused by pneumococcus.
The total medical and societal costs ofotitis
media in children under the age of 5,
including treatment expenses and lost wages
of caregivers, exceed $5 billion each year.
The newest finding, however, means that
"one million children are not [going to be]
coming to the doctor," says Shinefield.
"That's one million fewer prescriptions a
year that may be ineffective and contribute
to antibiotic resistance."
Carol Potera
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